EVFM - Evofem's Phexxi birth control method prevented 99% of pregnancies post analysis shows

Evofem Biosciences (NASDAQ:EVFM) on Thursday said a post analysis of its phase 3 trial evaluating Phexxi showed that the birth control method prevented 99% of pregnancies. The analysis was based on 101 pregnancies in about 1.2K women who used Phexxi over 24.2K acts of intercourse. Phexxi was approved by the U.S. FDA in May 2020 based on the results of the late-stage trial, called AMPOWER, which enrolled about 1.3K women in the U.S., as well as combined safety data from AMPOWER and a previous late-stage trial called AMP-001. EVFM's Phexxi works by modulating vaginal pH levels which in turn immobilizes the sperm. Phexxi is not effective when used after intercourse. EVFM stock -3.1% to $0.29 in morning trading.

For further details see:

Evofem's Phexxi birth control method prevented 99% of pregnancies, post analysis shows